drugset / Trial / NCT00688636
Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery
RandomizedSingle-groupDouble-blindPrevention
Summary
A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative infliximab or placebo
Timeline
- Start
- 2005-01
- Primary completion
- 2008-08
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |